Turn Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
GX-03 phase II trial for atopic dermatitis advances to an optimized stage two after interim analysis showed strong efficacy and safety, especially in patients with higher pruritus scores. The study uses a stratified, adaptive design and targets a phase II readout in Q4 2026.
-
GX-03, a novel topical therapy, demonstrated strong efficacy and safety in phase II eczema trials, with rapid onset and no adverse events. The company is expanding into toenail fungus and other inflammatory indications, supported by robust IP, a lean operation, and a strong leadership team.
-
A novel polymer-based ointment with first-in-class IL-36/IL-31 inhibition is advancing through a phase II eczema trial, with interim and top-line data expected in Q2 2026. The asset also shows promise in onychomycosis and other dermatology indications, supported by strong safety, efficacy, and patent protection.
-
The company is advancing a novel topical therapy for moderate to severe eczema, with a large phase II trial underway and interim results expected in Q2 2026. Its lead asset, GX-03, shows strong safety and efficacy, with plans for phase III trials in both eczema and onychomycosis.